TY - THES A1 - Grotemeyer, Alexander T1 - Characterisation and application of new optogenetic tools in \(Drosophila\) \(melanogaster\) T1 - Charakterisierung und Anwendung neuer optogenetischer Werkzeuge in \(Drosophila\) \(melanogaster\) N2 - Since Channelrhodopsins has been described first and introduced successfully in freely moving animals (Nagel et al., 2003 and 2005), tremendous impact has been made in this interesting field of neuroscience. Subsequently, many different optogenetic tools have been described and used to address long-lasting scientific issues. Furthermore, beside the ‘classical’ Channelrhodopsin-2 (ChR2), basically a cation-selective ion channel, also altered ChR2 descendants, anion selective channels and light-sensitive metabotropic proteins have expanded the optogenetic toolbox. However, in spite of this variety of different tools most researches still pick Channelrhodopsin-2 for their optogenetic approaches due to its well-known kinetics. In this thesis, an improved Channelrhodopsin, Channelrhodopsin2-XXM (ChR2XXM), is described, which might become an useful tool to provide ambitious neuroscientific approaches by dint of its characteristics. Here, ChR2XXM was chosen to investigate the functional consequences of Drosophila larvae lacking latrophilin in their chordotonal organs. Finally, the functionality of GtACR, was checked at the Drosophila NMJ. For a in-depth characterisation, electrophysiology along with behavioural setups was employed. In detail, ChR2XXM was found to have a better cellular expression pattern, high spatiotemporal precision, substantial increased light sensitivity and improved affinity to its chromophore retinal, as compared to ChR2. Employing ChR2XXM, effects of latrophilin (dCIRL) on signal transmission in the chordotonal organ could be clarified with a minimum of side effects, e.g. possible heat response of the chordotonal organ, due to high light sensitivity. Moreover, optogenetic activation of the chordotonal organ, in vivo, led to behavioural changes. Additionally, GtACR1 was found to be effective to inhibit motoneuronal excitation but is accompanied by unexpected side effects. These results demonstrate that further improvement and research of optogenetic tools is highly valuable and required to enable researchers to choose the best fitting optogenetic tool to address their scientific questions. N2 - Seit dem Channelrhodopsine das erste Mal beschrieben und erfolgreich in lebende Tiere eingebracht wurden (Nagel et al., 2003 und 2005), kam es zu einem beträchtlichen Fortschritt in diesem interessanten Gebiet der Neurowissenschaften. In der nachfolgenden Zeit wurden viele verschiedene optogenetische Werkzeuge beschrieben und zur Bearbeitung neurowissenschaftlicher Fragestellungen angewandt. Des Weiteren haben neben dem „klassischen“ Channelrhodopsin-2 (ChR2), ein im Wesentlichen Kation selektiver Kanal, auch modifizierte ChR2 Abkömmlinge, Anion selektive Kanäle und Licht sensitive metabotrope Proteine, die opotogenetische Werkzeugkiste erweitert. Dennoch greifen die meisten Wissenschaftler trotz der Vielfalt an optogenetischen Werkzeugen meist noch zu Channelrhodopsin-2, da seine Wirkungseigenschaften sehr gut erforscht sind. In der nachfolgenden Arbeit wird ein weiterentwickeltes Channelrhodopsin, Channelrhodopsin2-XXM (ChR2XXM), beschrieben. Aufgrund seiner vielfältigen Eigenschaften stellt es ein vielversprechendes Werkzeug dar, vor allem für zukünftige neurowissenschaftliche Forschungsarbeiten. Hierbei wurde ChR2XXM eingesetzt, um zu untersuchen welche Auswirkungen das Fehlen von Latrophilin im Chordotonal Organ von Drosophilalarven hat. Schließlich wurde noch die Funktionalität von GtACR an der neuromuskulären Endplatte der Drosophila überprüft. Für die umfassende Charakterisierung wurden elektrophysiologische und verhaltensbasierte Experimente an Larven durchgeführt. Es konnte gezeigt werden, dass ChR2XXM aufgrund einer erhöhten Affinität zu dem Chromophore Retinal, im Vergleich zu ChR2 ein besseres zelluläres Expressionsmuster, eine bessere zeitliche Auflösung und eine erheblich höhere Lichtsensitiviät aufweist. Durch den Einsatz von ChR2XXM konnte, aufgrund der hohen Lichtsensitiviät, mit nur minimalen Nebeneffekten, wie z.B. mögliche Wärmeaktivierung des Chordotonalorgans, der Einfluss von Latrophilin (dCIRL) auf die Signaltransmission im Chordotonalorgan, aufgeklärt werden. Ferner führte eine optogenetische, in vivo, Aktivierung des Chordotonalorgans zu Verhaltensänderungen. Zusätzlich konnte gezeigt werden, dass GtACR1 zwar effektiv motoneuronale Erregung inhibieren kann, dies aber von unerwarteten Nebeneffekten begleitet wird. Diese Ergebnisse zeigen auf, dass weitere Forschung und Verbesserungen im Bereich der optogenetischen Werkzeuge sehr wertvoll und notwendig ist, um Wissenschaftlern zu erlauben das am besten geeignetste optogenetische Werkzeug für ihre wissenschaftlichen Fragestellungen auswählen zu können. KW - Optogenetik KW - Taufliege KW - Elektrophysiologie KW - Channelrhodopsin-2 KW - optogenetics KW - Drosophila melanogaster KW - Channelrhodopsin KW - Electrophysiology Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-178793 ER - TY - JOUR A1 - Rauschenberger, Lisa A1 - Behnke, Jennifer A1 - Grotemeyer, Alexander A1 - Knorr, Susanne A1 - Volkmann, Jens A1 - Ip, Chi Wang T1 - Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson’s disease JF - Neurobiology of Disease N2 - The pathogenesis of Parkinson's disease (PD) is closely interwoven with the process of aging. Moreover, increasing evidence from human postmortem studies and from animal models for PD point towards inflammation as an additional factor in disease development. We here assessed the impact of aging and inflammation on dopaminergic neurodegeneration in the hm\(^{2}\)α-SYN-39 mouse model of PD that carries the human, A30P/A53T double-mutated α-synuclein gene. At 2–3 months of age, no significant differences were observed comparing dopaminergic neuron numbers of the substantia nigra (SN) pars compacta of hm\(^{2}\)α-SYN-39 mice with wildtype controls. At an age of 16–17 months, however, hm\(^{2}\)α-SYN-39 mice revealed a significant loss of dopaminergic SN neurons, of dopaminergic terminals in the striatum as well as a reduction of striatal dopamine levels compared to young, 2–3 months transgenic mice and compared to 16–17 months old wildtype littermates. A significant age-related correlation of infiltrating CD4+ and CD8\(^{+}\) T cell numbers with dopaminergic terminal loss of the striatum was found in hm\(^{2}\)α-SYN-39 mice, but not in wildtype controls. In the striatum of 16–17 months old wildtype mice a slightly elevated CD8\(^{+}\) T cell count and CD11b\(^{+}\) microglia cell count was observed compared to younger aged mice. Additional analyses of neuroinflammation in the nigrostriatal tract of wildtype mice did not yield any significant age-dependent changes of CD4\(^{+}\), CD8\(^{+}\) T cell and B220\(^{+}\) B cell numbers, respectively. In contrast, a significant age-dependent increase of CD8\(^{+}\) T cells, GFAP\(^{+}\) astrocytes as well as a pronounced increase of CD11b+ microglia numbers were observed in the SN of hm\(^{2}\)α-SYN-39 mice pointing towards a neuroinflammatory processes in this genetic mouse model for PD. The findings in the hm\(^{2}\)α-SYN-39 mouse model strengthen the evidence that T cell and glial cell responses are involved in the age-related neurodegeneration in PD. The slow and age-dependent progression of neurodegeneration and neuroinflammation in the hm\(^{2}\)α-SYN-39 PD rodent model underlines its translational value and makes it suitable for studying anti-inflammatory therapies. KW - Parkinson's disease KW - neuroinflammation KW - neurodegeneration Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300629 VL - 171 ER - TY - JOUR A1 - Grotemeyer, Alexander A1 - McFleder, Rhonda Leah A1 - Wu, Jingjing A1 - Wischhusen, Jörg A1 - Ip, Chi Wang T1 - Neuroinflammation in Parkinson’s disease – putative pathomechanisms and targets for disease-modification JF - Frontiers in Immunology N2 - Parkinson’s disease (PD) is a progressive and debilitating chronic disease that affects more than six million people worldwide, with rising prevalence. The hallmarks of PD are motor deficits, the spreading of pathological α-synuclein clusters in the central nervous system, and neuroinflammatory processes. PD is treated symptomatically, as no causally-acting drug or procedure has been successfully established for clinical use. Various pathways contributing to dopaminergic neuron loss in PD have been investigated and described to interact with the innate and adaptive immune system. We discuss the possible contribution of interconnected pathways related to the immune response, focusing on the pathophysiology and neurodegeneration of PD. In addition, we provide an overview of clinical trials targeting neuroinflammation in PD. KW - Parkinson’s disease KW - neuroinflammation KW - T cells KW - microglia KW - neurodegeneration KW - animal models KW - inflammatory cascades Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-274665 SN - 1664-3224 VL - 13 ER -